AbbVie is entering the obesity treatment market with a $2.3bn licensing agreement to acquire rights to a long-acting amylin ...

AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services ...

Stifel downgraded Novo Nordisk (NVO) to Hold from Buy with a price target of DKK 700, down from DKK 780. Novo is “no longer the same stock that ...

Goldman Sachs analysts added Novo Nordisk (NVO) to the firm’s European Conviction List as part of its monthly update. Novo Nordisk’s recent ...

India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes ...

Additional investment and resources will accelerate Biocomposites' international expansion and innovation in products for use in infection management HELLERUP, Denmark, LONDON and KEELE ...

We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on ValueInvestorsClub by cable888. In this article, we will ...

Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...

In the early aughts, Paula Deen was a powerhouse in the food world. Her career over the years has had its share of scandalous ...

Novo Nordisk A/S, BlackRock, Blackstone, Apollo Global Management, and Welltower are the five Growth stocks to watch today, ...

The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and ...